Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 476

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 476
---
913 | ​ | ​ |
| ​ | Class A common stock subject to possible redemption at December 31, 2022  | ​ | ​ | ​ | ​ |   15,127,621 | ​ | ​ |
| ​ | Less: Remeasurement of carrying value to redemption value                 | ​ | ​ | ​ | ​ |     -420,786 | ​ | ​ |
| ​ | Less: 2023 adjustment to share price for shares redeemed in December 2022 | ​ | ​ | ​ | ​ |     -298,431 | ​ | ​ |
| ​ | Less: Shares redeemed in September 2023                                   | ​ | ​ | ​ | ​ |  -10,358,754 | ​ | ​ |
| ​ | Class A common stock subject to possible redemption at December 31, 2023  | ​ | ​ | ​ | $ |    4,049,650 | ​ | ​ |

Warrants — Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the initial stockholders or their affiliates, without taking into account any Founder Shares held by the initial stockholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A common stock during the 20 trading day period starting on the trading day after the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the